CRF Health Announces Global Partnership with Vodafone
CRF Health, a global provider of electronic Clinical Outcome Assessment solutions for the life sciences industry, announced a new partnership with Vodafone.
CRF Health, a global provider of electronic Clinical Outcome Assessment (eCOA) solutions for the life sciences industry, announced a new partnership with Vodafone. CRF Health will use Vodafone’s global Machine-to-Machine (M2M) platform to offer an enhanced service to clinical trial operators and their patients. The agreement provides for mobile data sending in clinical trials using the TrialMax® eCOA platform. Clinical trial sponsors running global studies will receive reliable connectivity, instant access, security and integration to data through Vodafone’s global network.
Read the full release here.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
